We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.9B
1-Year Est. Return 169.69%
This Fund
S&P 500
This Quarter Est. Return
+26.15%
1 Year Est. Return
+169.69%
3 Year Est. Return
+507.65%
5 Year Est. Return
+746.04%
10 Year Est. Return
–
AUM
$2.9B
AUM Growth
+$433M
Cap. Flow
-$46.5M
Cap. Flow %
-1.6%
Top 10 Hldgs %
48.91%
Holding
114
New
21
Increased
25
Reduced
41
Closed
17

Top Buys

Rank Stock Value
1
PODD icon
Insulet
PODD
+$81.1M
2
INSP icon
Inspire Medical Systems
INSP
+$64.3M
3
RIGL icon
Rigel Pharmaceuticals
RIGL
+$56.6M
4
CELC icon
Celcuity
CELC
+$48.5M
5
PBLS
Parabilis Medicines Inc
PBLS
+$40.5M

Top Sells

Rank Stock Value
1
TWST icon
Twist Bioscience
TWST
+$73M
2
KRYS icon
Krystal Biotech
KRYS
+$63.9M
3
PRAX icon
Praxis Precision Medicines
PRAX
+$48.4M
4
TGTX icon
TG Therapeutics
TGTX
+$45.1M
5
VCEL icon
Vericel Corp
VCEL
+$39.2M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRYS icon
1
Krystal Biotech
KRYS
$10.6B
$349M 12.03%
939,254
-213,833
-19% -$63.9M
CELC icon
2
Celcuity
CELC
$4.68B
$178M 6.14%
1,704,318
+419,940
+33% +$48.5M
TGTX icon
3
TG Therapeutics
TGTX
$8.57B
$161M 5.54%
2,927,895
-1,101,424
-27% -$45.1M
PODD icon
4
Insulet
PODD
$10.2B
$160M 5.5%
1,049,000
+486,500
+86% +$81.1M
NVCR icon
5
NovoCure
NVCR
$2.09B
$150M 5.18%
9,913,401
-578,990
-6% -$8.76M
UTHR icon
6
United Therapeutics
UTHR
$20.9B
$122M 4.21%
225,587
+38,400
+21% +$21.6M
INSP icon
7
Inspire Medical Systems
INSP
$1.82B
$86.2M 2.97%
1,931,436
+1,355,137
+235% +$64.3M
RIGL icon
8
Rigel Pharmaceuticals
RIGL
$909M
$72.1M 2.49%
1,843,504
+1,833,504
+18,335% +$56.6M
ANIP icon
9
ANI Pharmaceuticals
ANIP
$1.64B
$71.8M 2.48%
867,760
+47,517
+6% +$3.81M
BBNX
10
Beta Bionics
BBNX
$874M
$68.8M 2.37%
4,393,714
+39,213
+0.9% +$466K
VCEL icon
11
Vericel Corp
VCEL
$2.06B
$64.9M 2.24%
1,459,152
-1,089,927
-43% -$39.2M
PRAX icon
12
Praxis Precision Medicines
PRAX
$9.82B
$59.4M 2.05%
177,517
-153,000
-46% -$48.4M
GERN icon
13
Geron
GERN
$1.01B
$54.8M 1.89%
42,808,659
+1,300,000
+3% +$1.83M
ALKS icon
14
Alkermes
ALKS
$7.73B
$53.9M 1.86%
1,029,252
-941,612
-48% -$36.8M
ERAS icon
15
Erasca
ERAS
$5.66B
$49.5M 1.7%
+2,700,000
New +$38.6M
NPCE icon
16
Neuropace
NPCE
$511M
$46.3M 1.59%
2,911,122
-21,085
-0.7% -$339K
PGNY icon
17
Progyny
PGNY
$1.99B
$46.2M 1.59%
1,602,000
-465,000
-22% -$10.4M
INDV icon
18
Indivior Pharmaceuticals
INDV
$4.12B
$43.7M 1.5%
1,064,000
-210,000
-16% -$7.62M
PBLS
19
Parabilis Medicines Inc
PBLS
$4.99B
$40.1M 1.38%
+1,465,070
New +$40.5M
FOCL
20
EDAP TMS S.A.
FOCL
$191M
$37.9M 1.3%
7,309,254
– –
GMED icon
21
Globus Medical
GMED
$10.5B
$37M 1.28%
468,922
-260,545
-36% -$22.1M
RCUS icon
22
Arcus Biosciences
RCUS
$3.78B
$36M 1.24%
1,168,738
+716,755
+159% +$17.7M
SNDX icon
23
Syndax Pharmaceuticals
SNDX
$1.84B
$35.6M 1.23%
1,628,039
-98,869
-6% -$2.06M
NRIX icon
24
Nurix Therapeutics
NRIX
$2.71B
$35.5M 1.22%
1,465,163
+527,000
+56% +$8.98M
LEGN icon
25
Legend Biotech
LEGN
$4.19B
$34.8M 1.2%
+1,205,000
New +$32.5M
1
2 3 4 5

Similar funds

GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
LSA
Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return
7WCP
71 West Capital Partners Boston, Massachusetts $2.89B AUM
ACM
Aquatic Capital Management Chicago, Illinois $2.91B AUM 27.09% 1-Year Est. Return
HWA
Heritage Wealth Advisors Richmond, Virginia $2.91B AUM 24.25% 1-Year Est. Return
JC
JB Capital Wethersfield, Connecticut $2.89B AUM 29.25% 1-Year Est. Return
WPW
Waldron Private Wealth Bridgeville, Pennsylvania $2.89B AUM 23.18% 1-Year Est. Return
BWL
Bogart Wealth LLC Mclean, Virginia $2.92B AUM 23.85% 1-Year Est. Return

Soleus Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Soleus Capital Management held 114 positions worth $2.9B, up 18% from $2.47B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Soleus Capital Management's Q2 2026 filing shows 21 new, 25 increased, 41 reduced and 17 closed positions. Its largest new stake was Parabilis Medicines Inc: 1,465,070 shares worth $40.1M. The largest sale was Twist Bioscience, an estimated $73M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Soleus Capital Management's largest Q2 2026 buy was Parabilis Medicines Inc: 1,465,070 shares worth $40.1M.
  • Soleus Capital Management added most to Insulet in Q2 2026, an estimated $81.1M increase.
  • Soleus Capital Management's biggest Q2 2026 reduction was Twist Bioscience, cutting an estimated $73M.
  • Soleus Capital Management fully exited Vaxcyte in Q2 2026, selling an estimated $22.4M.
  • Soleus Capital Management's ten largest holdings make up 49% of its $2.9B portfolio in Q2 2026.
  • Soleus Capital Management opened 21 new positions and closed 17 in Q2 2026.
  • Soleus Capital Management's portfolio value rose 18% quarter-over-quarter to $2.9B.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.